装有5-甲的益生菌-益生菌脂质体调节肠道微生物群,以改善结肠直肠癌化疗
Xujie Sun1,2, Xiaoting Shan2, Binyu Zhu2
1Lingang Laboratory, Shanghai, 200031, China.
Advanced healthcare materials
|December 16, 2024
概括
这项研究介绍了FLSK,一种新的脂质体药物递送系统,结合了益生菌和益生菌来增强结直肠癌 (CRC) 的化疗. FLSK改善了药物输送,增强了抗瘤免疫力,并调节了肠道微生物群,以更好地治疗CRC.
科学领域:
- 在瘤学瘤学.
- 微生物学 微生物学
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 肠道微生物群在抑制结直肠癌 (CRC) 进展方面发挥着至关重要的作用.
- 与传统方法相比,益生菌和益生菌为微生物群调节提供了更安全的替代方案.
- 5-Fluorouracil (5-FU) 是一种标准的CRC化疗,具有较差的药理动力学和显著的副作用.
研究的目的:
- 开发一种新的药物输送系统,将化疗与肠道微生物群调节结合起来,用于CRC.
- 为了提高5-FU化疗的疗效和减少其副作用.
- 研究益生菌,益生菌和化疗对CRC治疗的联合作用.
主要方法:
- 用益生菌Sxy和益生菌相关脂DPE修改的5FU载体的构建,称为FLSK.
- 在小鼠模型中评估FLSK的肠道运输,药物释放概况和体内抗瘤疗效.
- 评估FLSK对抗瘤免疫力和肠道微生物群组成的影响.
主要成果:
- FLSK证明了长时间的肠道运输和5-FU的持续释放,确保了瘤部位的高药物度.
- 在CRC小鼠模型中,FLSK显著抑制了瘤生长,并延长了CRC小鼠的生存期.
- FLSK被证明可以增强抗瘤免疫力,并积极调节肠道微生物群的组成.
结论:
- 通过将化疗与肠道微生物群调节相结合,FLSK代表了协同CRC治疗的有希望的策略.
- 开发的脂质体系统有效地克服了传统的5 - FU管理的局限性.
- 在结直肠癌治疗中,FLSK具有改善患者治疗结果的潜力.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:21Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K